• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Oncology biotech Tyra Biosciences files for a $100 million IPO

firstwordpharmaAugust 23, 2021

Tag: Tyra , FGFR , IPO

Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.

The company is using its proprietary SNÅP platform to generate next-generation candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options.

Its lead candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

Tyra anticipates filing an investigational new drug application for TYRA-300 in mid-2022.


Previous:South Korea to get more Moderna COVID shots in boost to vaccination effort

Next:UK scientists look at reducing boosters to save vaccine for rest of the world

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Oncology biotech Tyra Biosciences files for a $100 million IPO | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Tert-butyl-2-bromoisobutyrate

Tert-butyl-2-bromoisobutyrate
hmb-ca，beta-hydroxy-beta-Methyl Butyrate Calcium Salt

hmb-ca，beta-hydroxy-beta-Methyl Butyrate Calcium Salt
(2R,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-2-Methyl-4-(1H-1,2,4-triazol-1-yl)thiobutyraMide

(2R,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-2-Methyl-4-(1H-1,2,4-triazol-1-yl)thiobutyraMide
Siponimod Intermediate

Siponimod Intermediate
(2R,3R)-3-(2,5-Difluorophenyl) -3-hydroxy-2-methyl-4-(1H-1,2, 4-triazol-1-yl)thiobutyramide sulfate

(2R,3R)-3-(2,5-Difluorophenyl) -3-hydroxy-2-methyl-4-(1H-1,2, 4-triazol-1-yl)thiobutyramide sulfate
tert-butyl bromoisobutyrate

tert-butyl bromoisobutyrate
ethyl 2-bromoisobutyrate

ethyl 2-bromoisobutyrate
Estradiol Benzoate Butyrate

Estradiol Benzoate Butyrate
Ethyl-α-bromobutyrate

Ethyl-α-bromobutyrate
R-(+)- Alpha Lipoic Acid (RALA)

R-(+)- Alpha Lipoic Acid (RALA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service